Quantcast
Last updated on April 17, 2014 at 15:30 EDT

Latest Diagnostic tests Stories

2009-06-10 10:58:39

The most important factors for a successful stay in hospital short-stay units (SSUs) are the types of diagnostic tests performed and whether or not specialty consultations are needed. When hospitalists staff these units, they can ensure that only patients who need readily accessible services are admitted. These are the findings of a study published in the Journal of Hospital Medicine.SSUs provide an alternative to traditional inpatient services for patients and exist in one-third of hospitals...

2009-06-08 15:01:00

Ticker Symbol: CUR Gen-Probe to initiate FDA pivotal clinical study for the PCA3 prostate cancer test QUEBEC CITY, June 8 /PRNewswire-FirstCall/ - DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced a net loss of $2,622,237 or $0.06 per share for the second quarter ending April 30, 2009. This net loss reflects in part the budgeted sales and marketing initiatives to promote the Previstage(TM) GCC...

2009-06-02 06:30:00

AUSTIN, Texas, June 2 /PRNewswire/ -- Rules-Based Medicine, Incorporated (RBM), the leading biomarker testing service, today announced that Tony Barnes, Ph.D., MBA, has joined the Company as vice president, clinical diagnostics. Barnes will provide strategic marketing and operational leadership as RBM commercializes new biomarker-based diagnostic tests. RBM, an established provider of multiplex biomarker assays for improved drug development, has programs to develop new diagnostic products...

2009-06-01 12:00:00

- THEROS CancerTYPE ID(R) predicts cancer origin with 75 percent accuracy in patients whose primary cancer was 'unknown' using traditional diagnostics - SAN DIEGO, June 1 /PRNewswire/ -- bioTheranostics, a bioMerieux company that discovers, develops and commercializes new molecular diagnostic tests in oncology, announced that a recent study demonstrated the company's THEROS CancerTYPE ID(R) molecular diagnostic test predicted cancer origin with 75 percent accuracy in patients whose primary...

2009-05-11 10:48:00

Collaboration with Noted Neurologists to Plan Next Clinical Studies OMAHA, Neb. and HOUSTON, May 11 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) and Power3 Medical Products, Inc. (OTC Bulletin Board: PWRM), announced the clinical introduction of the NuroPro(R) AD and NuroPro(R) PD tests for Alzheimer's and Parkinson's disease at the 2009 American Academy of Neurology meeting in Seattle, WA. The NuroPro tests help clinicians distinguish patients with Alzheimer's and...

2009-04-29 06:00:00

- Malaysian Ministry of Health provides grant to develop blood-based diagnostic tests for liver cancer, Hepatitis B and nasopharyngeal cancer - TORONTO, April 29 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it will undertake a two-year joint project to develop blood-based diagnostic tests for liver cancer, Hepatitis B...

2009-04-28 09:50:10

A new study, carried out in primary care units in Zanzibar and published in this week's issue of PLoS Medicine, evaluates the impact of rapid malaria tests on prescribing practice and clinical outcomes. The findings suggest that routine use of such tests may reduce the number of people who are inappropriately given antimalarial drugs. Currently, malaria in sub-Saharan Africa tends to be diagnosed on the basis of symptoms alone (i.e. fever). However, such symptoms are not very accurate and...

2009-04-07 06:00:00

HOUSTON, April 7 /PRNewswire/ -- SeqWright Inc., an international leader in the field of contract genomic services, announced today its involvement in Hologic's (formerly Third Wave Technologies) successful clinical trials of two Human Papillomavirus (HPV) in vitro diagnostic tests. SeqWright provided FDA submission quality DNA sequencing of multiple HPV strains and bioinformatics support to validate two Hologic HPV diagnostic tests; Cervista HPV High Risk (HR) and Cervista HPV 16/18, in...

2009-03-30 11:27:00

- Legislation Seeks to Ensure Medicare Beneficiaries Have Access to Life-Saving Diagnostic Tests, Encourage Continued Innovation of Personalized Medicine - WASHINGTON, March 30 /PRNewswire-USNewswire/ -- The Coalition for 21st Century Medicine today announced its full endorsement for the Patient Access to Critical Lab Tests Act, legislation introduced in the U.S. House of Representatives on March 25th by Representatives Jason Altmire (D-PA), Anna Eshoo (D-CA) and Tim Murphy (R-PA). The...

2009-03-17 15:30:00

Ticker Symbol: CUR PCA3 royalty revenue triples and GCC sales start QUEBEC CITY, March 17 /PRNewswire-FirstCall/ - DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering lab services, announced a net loss of $3,440,655 or $0.08 per share for the first quarter ending January 31, 2009. These results are substantially in line with Management expectations. They reflect budgeted sales and marketing initiatives to promote the...